Kyverna Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative cell therapies for autoimmune diseases. Its flagship product, KYV-101, is a cutting-edge treatment designed for lupus nephritis and other severe conditions like systemic sclerosis and multiple sclerosis. Additionally, Kyverna is working on KYV-201, aiming to broaden its impact across multiple autoimmune diseases. With roots tracing back to 2018 and a rebranding from BAIT Therapeutics in 2019, Kyverna is based in Emeryville, California, leading the charge in autoimmune disease treatment.
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
